CoChat

In vivo priming of human mesenchymal stem cells with hepatocyte growth factor–engineered mesenchymal stem cells promotes therapeutic potential for cardiac repair

Open access

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Priming human BM-MSCs with engineered HGF-MSCs in vivo significantly improves therapeutic potential for myocardial infarction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aay6994

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 In vitro characterization of primed BM-MSCs by HGF-eMSC coculture. (A) Schematic diagram showing the in vitro coculture model of BM-MSCs with HGF-eMSCs. (B) qRT-PCR analysis of relative mRNA expression of multiple angiogenic factors in the unprimed BM-MSCs, primed BM-MSCs with HGF-eMSCs at 3 days after cocultures, or BM-MSCs receiving HGF cytokine (50 ng/ml) for 3 days. The y axis represents relative mRNA expression of target genes to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). †P < 0.05 compared to unprimed BM-MSC group; n = 3 per group. (C) Measurement of secreted VEGF from unprimed or primed BM-MSCs by using ELISA. P < 0.05 compared to unprimed BM-MSC group. (D) Matrigel plug assay. The 10% hMSC-CM was treated to human umbilical cord endothelial cells (HUVECs) on Matrigel to examine the vasculogenic potential. Representative images of tubes formed on Matrigel and quantification summary. n = 3 per group. (E) Endothelial cell (EC) migration assay. The HUVECs were incubated with 10% CM harvested from hMSC cultures (hMSC-CM) or control media to evaluate the migration capability. Representative images under an inverted microscope and quantification summary are shown. *P < 0.05 compared to each group; n = 5 per group. (F) Treatment with CM from primed BM-MSCs increased cell survival after serum starvation for 5 days determined by the annexin V and cholecystokinin-8 (CCK-8) assay. *P < 0.05 compared to unprimed CM treated group; n = 3 per group. PI, propidium iodide; OD, optical density.
Fig. 1 In vitro characterization of primed BM-MSCs by HGF-eMSC coculture. (A) Schematic diagram showing the in vitro coculture model of BM-MSCs with HGF-eMSCs. (B) qRT-PCR analysis of relative mRNA expression of multiple angiogenic factors in the unprimed BM-MSCs, primed BM-MSCs with HGF-eMSCs at 3 days after cocultures, or BM-MSCs receiving HGF cytokine (50 ng/ml) for 3 days. The y axis represents relative mRNA expression of target genes to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). †P < 0.05 compared to unprimed BM-MSC group; n = 3 per group. (C) Measurement of secreted VEGF from unprimed or primed BM-MSCs by using ELISA. P < 0.05 compared to unprimed BM-MSC group. (D) Matrigel plug assay. The 10% hMSC-CM was treated to human umbilical cord endothelial cells (HUVECs) on Matrigel to examine the vasculogenic potential. Representative images of tubes formed on Matrigel and quantification summary. n = 3 per group. (E) Endothelial cell (EC) migration assay. The HUVECs were incubated with 10% CM harvested from hMSC cultures (hMSC-CM) or control media to evaluate the migration capability. Representative images under an inverted microscope and quantification summary are shown. *P < 0.05 compared to each group; n = 5 per group. (F) Treatment with CM from primed BM-MSCs increased cell survival after serum starvation for 5 days determined by the annexin V and cholecystokinin-8 (CCK-8) assay. *P < 0.05 compared to unprimed CM treated group; n = 3 per group. PI, propidium iodide; OD, optical density.CC BY-NC · PubMed Central
Fig. 2 Direct cytoprotective effects of HGF-eMSC CM on cardiomyocytes undergoing simulated ischemic injury. Treatment with either HGF-eMSC CM or HGF cytokine significantly promoted cell survival after serum starvation for 5 days determined by the live and dead assay (A to B) and CCK-8 assay (C). *P < 0.05 compared to each group; n = 3 per group.
Fig. 2 Direct cytoprotective effects of HGF-eMSC CM on cardiomyocytes undergoing simulated ischemic injury. Treatment with either HGF-eMSC CM or HGF cytokine significantly promoted cell survival after serum starvation for 5 days determined by the live and dead assay (A to B) and CCK-8 assay (C). *P < 0.05 compared to each group; n = 3 per group.CC BY-NC · PubMed Central
Fig. 3 Schematic illustration for manufacturing BM-MSC/HGF-eMSC patch using hdECM. (A) Procedures for preparing hdECM bioink. (B) Macroscopic view and illustration of 3D printing system used to produce the polycaprolactone (PCL) platform. (C) Shape of hMSC patch (hMSC-PA). Scale bar, 1 mm. (D) Epicardially implanted BM-MSC/HGF-eMSC patch in MI-induced hearts (E) and at 8 weeks after implantation. Photo credit: Bong-Woo Park, The Catholic University of Korea.
Fig. 3 Schematic illustration for manufacturing BM-MSC/HGF-eMSC patch using hdECM. (A) Procedures for preparing hdECM bioink. (B) Macroscopic view and illustration of 3D printing system used to produce the polycaprolactone (PCL) platform. (C) Shape of hMSC patch (hMSC-PA). Scale bar, 1 mm. (D) Epicardially implanted BM-MSC/HGF-eMSC patch in MI-induced hearts (E) and at 8 weeks after implantation. Photo credit: Bong-Woo Park, The Catholic University of Korea.CC BY-NC · PubMed Central
Fig. 4 Implantation of the BM-MSC/HGF-eMSC patch improved cardiac function and reduced adverse cardiac remodeling. (A to B) LVEF and EF change at 8 weeks after intervention. CON, control. (C to D) FS and FS change at 8 weeks after intervention. (E) LVIDd. (F) LVISd. (G) SWT. (H) PWT. *P < 0.05 compared to sham group; †P < 0.05 compared to control group; ‡P < 0.05 compared to BM-MSC group; §P < 0.05 compared to HGF-eMSC group. n = 5 to 9 for each group. N.S., not significant. (I) Representative images from the four experimental groups showing cardiac fibrosis after staining with Masson’s trichrome in the hearts harvested 8 weeks after MI and (J) their quantification results such as percentage of viable myocardium and (K) percent fibrosis. *P < 0.05 compared to control group; †P < 0.05 compared to BM-MSC group; ‡P < 0.05 compared to HGF-eMSC group. n = 5 to 6 for each group. Scale bar, 5 mm.
Fig. 4 Implantation of the BM-MSC/HGF-eMSC patch improved cardiac function and reduced adverse cardiac remodeling. (A to B) LVEF and EF change at 8 weeks after intervention. CON, control. (C to D) FS and FS change at 8 weeks after intervention. (E) LVIDd. (F) LVISd. (G) SWT. (H) PWT. *P < 0.05 compared to sham group; †P < 0.05 compared to control group; ‡P < 0.05 compared to BM-MSC group; §P < 0.05 compared to HGF-eMSC group. n = 5 to 9 for each group. N.S., not significant. (I) Representative images from the four experimental groups showing cardiac fibrosis after staining with Masson’s trichrome in the hearts harvested 8 weeks after MI and (J) their quantification results such as percentage of viable myocardium and (K) percent fibrosis. *P < 0.05 compared to control group; †P < 0.05 compared to BM-MSC group; ‡P < 0.05 compared to HGF-eMSC group. n = 5 to 6 for each group. Scale bar, 5 mm.CC BY-NC · PubMed Central
Fig. 5 Survival of in vivo primed BM-MSC in MI hearts and their effects on vascular regeneration and cardioprotection. (A to C) Survival of hMSCs and HGF-eMSC within the cardiac patch after 8 weeks from implantation into the MI-induced rat hearts and their quantification summary. (A) Representative images of hMSCs [DiI (1.1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocynanine perchlorate), red], HGF-eMSC [DiO (3,3ʹ-Dioctadecyloxacarbocyanine perchlorate), green], TUNEL signal (gray), and 4′,6-diamidino-2-phenylindole (DAPI) for nucleus (blue) within the patch made by using hdECM. (B) Number of either DiI- or DiO-positive MSCs. (C) Number of TUNEL signal–positive MSCs. Scale bars, 50 μm. n = 5 per group. (D) Representative images of capillaries stained with fluorescein isothiocyanate (FITC)–IB4 (green) on the infarct zone (IZ), border zone (BZ), and remote zone at 8 weeks after MI and (E to G) their quantification summary in three areas. For quantification, the number of capillaries on five randomly selected fields in each heart was counted. Scale bars, 50 μm. *P < 0.05 compared to control group; †P < 0.05 compared to BM-MSC group; ‡P < 0.05 compared to HGF-eMSC group. n = 5 per group. (H) Representative immunostaining images with cardiac-specific TNNT2 (red), TUNEL signal (gray), and DAPI for nucleus (blue) at 8 weeks after MI and (I and J) their quantification summary. Scale bars, 50 μm. *P < 0.05 compared to control group; †P < 0.05 compared to BM-MSC group; ‡P < 0.05 compared to HGF-eMSC group. n = 5 to 9 for each group.
Fig. 5 Survival of in vivo primed BM-MSC in MI hearts and their effects on vascular regeneration and cardioprotection. (A to C) Survival of hMSCs and HGF-eMSC within the cardiac patch after 8 weeks from implantation into the MI-induced rat hearts and their quantification summary. (A) Representative images of hMSCs [DiI (1.1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocynanine perchlorate), red], HGF-eMSC [DiO (3,3ʹ-Dioctadecyloxacarbocyanine perchlorate), green], TUNEL signal (gray), and 4′,6-diamidino-2-phenylindole (DAPI) for nucleus (blue) within the patch made by using hdECM. (B) Number of either DiI- or DiO-positive MSCs. (C) Number of TUNEL signal–positive MSCs. Scale bars, 50 μm. n = 5 per group. (D) Representative images of capillaries stained with fluorescein isothiocyanate (FITC)–IB4 (green) on the infarct zone (IZ), border zone (BZ), and remote zone at 8 weeks after MI and (E to G) their quantification summary in three areas. For quantification, the number of capillaries on five randomly selected fields in each heart was counted. Scale bars, 50 μm. *P < 0.05 compared to control group; †P < 0.05 compared to BM-MSC group; ‡P < 0.05 compared to HGF-eMSC group. n = 5 per group. (H) Representative immunostaining images with cardiac-specific TNNT2 (red), TUNEL signal (gray), and DAPI for nucleus (blue) at 8 weeks after MI and (I and J) their quantification summary. Scale bars, 50 μm. *P < 0.05 compared to control group; †P < 0.05 compared to BM-MSC group; ‡P < 0.05 compared to HGF-eMSC group. n = 5 to 9 for each group.CC BY-NC · PubMed Central
Fig. 6 Schematic diagram of the underlying mechanism of in vivo priming of BM-MSCs with HGF-eMSC.
Fig. 6 Schematic diagram of the underlying mechanism of in vivo priming of BM-MSCs with HGF-eMSC.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 142

Metadata

Authors
Park, B.-W., Jung, S.-H., Das, S., Lee, S. M., Park, J.-H., Kim, H., Hwang, J.-W., Lee, S., Kim, H.-J., Kim, H.-Y., Jung, S., Cho, D.-W., Jang, J., Ban, K., & Park, H.-J.
Affiliations
  • The Catholic University of Korea Seoul St. Mary's Hospital (KR)
  • Pohang University of Science and Technology (KR)
  • City University of Hong Kong (HK)
  • Department of Biomedical Sciences, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR.
Corresponding author
  • Jang, Jinah
  • Ban, Kiwon
  • Park, Hun-Jun
Venue
Science Advances
Published
2020-03-27
Volume
6
Issue
13
Pages
eaay6994-eaay6994
ISSN
2375-2548 (ISSN-L)
OpenAlex
W3013134172
Cited by
133
References
25
Citations by year
2026: 12 · 2025: 18 · 2024: 24 · 2023: 19 · 2022: 30 · 2021: 23 · 2020: 7
FWCI
10.22
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • CityU Scholars (submittedVersion, cc-by-nc)
Funders
National Research Foundation of Korea grants (2016R1C1B2015529)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
Keywords
mesenchymal stem cells, bone marrow-derived stem cells, hepatocyte growth factor, in vivo priming, myocardial infarction, cardiac repair, epicardial implantation, vasculogenesis, vascular regeneration, cardiomyocyte survival, cardioprotection, cell transplantation
MeSH terms
Animals, Disease Models, Animal, Genetic Engineering, Heart Diseases, Humans, Myocardial Infarction, Swine, Gene Expression, Hepatocyte Growth Factor, Cell Culture Techniques, Myocytes, Cardiac, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.